Treatment of acute coronary syndrome with GLP-1
US6706689B2 · kind B2 · utility
94Cited by
3References
41Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2001 |
| Grant date | Mar 16, 2004 |
| Priority date | — |
| Expiry date | Jun 10, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.